Cereno Scientific AB
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Cereno Scientific is pioneering treatments to enhance and extend life. Cereno's innovative pipeline offers first-in-class disease-modifying treatments for rare cardiopulmonary disease. Lead candidate CS1 is HDAC inhibitor that works through epigenetic modulation and targets root mechanisms of PAH. CS1 is well-tolerated oral therapy with favorable safety profile that has shown encouraging efficacy signals of reverse remodeling in Phase IIa trial, including improvements in right heart function, functional class and patient quality of life. CS014 is NCE and HDAC inhibitor with multimodal MoA as epigenetic modulator, having potential to address underlying pathophysiology of several cardiopulmonary and fibrotic diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, focus for Phase II is PH-ILD. Cereno Scientific is also pursuing a preclinical program - CS585, an oral, highly potent and selective IP receptor agonist in rare thrombotic disorders.
Company HQ City:
Mölndal
Company HQ State:
Gothenburg
Company HQ Country:
Sweden
Year Founded:
2012
Lead Product in Development:
CS1 - Oral, once-daily delayed reformulation of VPA
CEO
CEO
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
Exchange
Nasdaq
Ticker
CRNO B
When you expect your next catalyst update?
June 2026
What is your next catalyst (value inflection) update?
CS1 Phase IIb Trial Initiation
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}